Detailed narrative
Quarterly Performance and Financial Inflection
Precipio achieved record quarterly consolidated revenue exceeding $7M in Q2 2026, advancing ~22% YoY from $5.7M in Q2 2025 and sequentially from approximately $6.7M in Q1 2026. The company reached an inflection in profitability, posting approximately $400,000 in adjusted EBITDA compared to negative $200,000 in Q1 2026. This $600,000 sequential turnaround was primarily driven by a top-line revenue increase of approximately $300,000 and a reduction in stock-based compensation expense of approximately $200,000. Cash from operations reached approximately $700,000, representing 10% of revenue, which increased cash balances by roughly $500,000 to over $3M without external financing.
Diagnostic Flywheel Model and Competitive Moat
Management detailed the strategic advantage of its diagnostic operating flywheel connecting clinical services to proprietary products. The company's clinical laboratory directly identifies diagnostic workflow, economic, and technical bottlenecks in cancer evaluation. Precipio invents, develops, and clinically validates proprietary solutions within its internal lab operations before commercializing them to external diagnostic laboratories. This approach ensures products meet real-world clinical and reimbursement hurdles and expands Precipio's addressable market without requiring additional physical laboratory buildouts.
Rapid AML Assay Clinical and Commercial Position
The acute myeloid leukemia (AML) rapid assay was highlighted as a core example of the company's innovation strategy. While conventional molecular laboratory turnaround times for AML range between 10 and 14 days, Precipio's assay delivers actionable molecular results within one day. This rapid turnaround addresses critical clinical urgency where AML patients are at risk of mortality within 48 hours. The company receives several weekly patient AML samples internally and is pursuing domestic and international sales alongside planned marketing collaborations and clinical studies.
Product Commercialization and Distributor Channel Strategy
Product business momentum accelerated as Q2 revenue expanded 35% sequentially to approximately $900,000, surpassing the previous record of $750,000 set in Q4 2025 by 21%. Commercial expansion was supported by adding approximately 10 new distributor representatives across partnerships with Thermo Fisher, McKesson, Medline, and Cardinal Health. The commercial team identified more than 25 new qualified customer accounts and conducted over 30 customer meetings in Q2, with management anticipating active account conversion during the second half of 2026.
Pathology Services Operations and Organic Growth
The Pathology division generated approximately $6.1M in revenue in Q2 2026, expanding modestly from $6.0M in Q1 2026. Management reiterated that while corporate resources are heavily targeted at scaling the higher-margin product division, pathology services remain foundational to generating steady recurring revenue and providing the clinical validation engine for R&D. Pathology operations are expected to continue steady organic growth through the remainder of the fiscal year.